Retatrutide Hype Outpaces Science as Lilly Phase 3 Triple Agonist Remains Unapproved
A nerdbot explainer separates retatrutide science from online hype: the Lilly triple agonist is unapproved, vial quality claims are thin, and pen stability is asserted rather than tested.